SIGLEC15 and cancer: The key immune checkpoints (CD274, CTLA-4, HAVCR2, LAG3, PDCD1, PDCD1LG2, SIGLEC15, and TIGIT) also had a significant relationship with DTYMK expression in approximately 20 kinds of cancers, except in MESO, PCPG, and UCS.